Study Summary
To evaluate the tolerability and safety of SENL101 in patients with relapsed or refractory CD7+ hematolymphoid malignancies.
Want to learn more about this trial?
Request More InfoInterventions
SENL101BIOLOGICAL
Patients will be treated with CD7 CAR-T cells
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Tongji Hospital | Wuhan | Hubei | China |